Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1681 in advanced solid tumors
NCT06737731Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1681 in malignant solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose at 12 months, Maximum Administered Dose at 12 months and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
SHR-1681
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06737731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737731.